Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

W1

Compound for prevention or treatment of Rhinovirus infection

Prof. Johannes Stöckl, Medical University of Vienna; Dr Guido Gualdoni, Medical University of Vienna

Medical University of Vienna


Challenge

Rhinoviruses are the major causative agent of the common cold and other respiratory tract infections. While billions of infections occur every year with patients suffering from symptoms such as runny nose, nasal congestion, sore throat, headache, and sleep deprivation, effective treatment or prevention strategies without risky side effects are lacking. Existing treatments focus on alleviating the symptoms of the infection, while antiviral agents are not available and the development of a vaccine has been unsuccessful so far because of the large number of rhinovirus serotypes.


Technology

Infection with rhinoviruses induces metabolic alterations in infected cells and a pronounced reprogramming of host cell metabolism. The proposed agent to treat rhinovirus infections is a simple sugar-derivative that prevents those metabolic changes, thus starving viral infection. The compound targets the cause of the disease by disrupting rhinovirus replication both in vitro and in vivo, thus promising a shorter duration of the infection with alleviation of symptoms.

Advantages:

  • Anti-viral agent stops virus proliferation  
  • Efficient & safe agent  
  • Low cost of compound  
  • High compatibility with other therapies 
  • Global market  
  • Ready-to-use medication  
  • Low probability of resistance development 

Commercial Opportunity

Collaboration

License or purchase


Development Status

Mouse model, established treatment strategy


Patent Situation

EP18154088 filed 30th Jan 2018 - Inhibition of infection with human rhinoviruses (HRV) by 2-deoxyglucose (2-DG)

PCT/EP2018/097060 filed 28th Dec 2018 - Inhibition of infection with human rhinoviruses (HRV) by 2-deoxyglucose (2-DG)


Further Reading

Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):E7158-E7165. Rhinovirus induces an anabolic reprogramming in host cell metabolism essential for viral replication. Gualdoni GA1,2, Mayer KA3, Kapsch AM3,4, Kreuzberg K3, Puck A3, Kienzl P5, Oberndorfer F6, Frühwirth K7, Winkler S7, Blaas D8, Zlabinger GJ3, Stöckl J3.


 

Compound for prevention or treatment of Rhinovirus infection